Related Experiment Video
Updated: Jun 20, 2026
10:31
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
[Potential therapeutic targets for diabetic nephropathy]
Yuichi Makino1, Masakazu Haneda
1Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical College.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 23, 2009
Summary
Diabetic nephropathy, a leading cause of kidney failure, requires new treatments. This review explores novel therapies targeting the complex mechanisms driving diabetic kidney disease progression.
Area of Science:
- Nephrology
- Endocrinology
- Biochemistry
Context:
- Diabetic nephropathy is the primary cause of end-stage renal disease globally.
- Current treatments focusing on blood glucose and pressure control slow progression but do not prevent nephropathy.
- Urgent need for novel therapeutic strategies to address unmet clinical needs in diabetic kidney disease.
Purpose:
- To review current concepts in novel targeted therapy for diabetic kidney complications.
- To discuss the pathological mechanisms underlying glucose-mediated microvascular damage in diabetic nephropathy.
- To highlight potential therapeutic targets for preventing diabetic nephropathy progression.
Summary:
- Diabetic nephropathy involves complex pathways including protein kinase C activation, inflammation, advanced glycation end products, and oxidative stress.
- Inhibiting these specific pathological mechanisms presents a promising therapeutic avenue.
- This review synthesizes current knowledge on innovative approaches for managing diabetic kidney disease.
Impact:
- Provides insights into potential new treatments for diabetic nephropathy.
- Highlights the importance of targeting specific molecular pathways.
- Contributes to the development of more effective strategies for preventing diabetic kidney complications and slowing disease progression.
Related Concept Videos
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...